Y Intercept Hong Kong Ltd Increases Holdings in BridgeBio Pharma, Inc. (NASDAQ:BBIO)

Y Intercept Hong Kong Ltd boosted its position in BridgeBio Pharma, Inc. (NASDAQ:BBIO) by 95.6% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 25,980 shares of the company’s stock after buying an additional 12,701 shares during the period. Y Intercept Hong Kong Ltd’s holdings in BridgeBio Pharma were worth $713,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds and other institutional investors also recently bought and sold shares of the business. First Bank & Trust acquired a new stake in BridgeBio Pharma during the 4th quarter valued at approximately $205,000. Handelsbanken Fonder AB lifted its position in BridgeBio Pharma by 16.6% during the fourth quarter. Handelsbanken Fonder AB now owns 37,950 shares of the company’s stock valued at $1,041,000 after purchasing an additional 5,400 shares during the period. State of New Jersey Common Pension Fund D boosted its holdings in BridgeBio Pharma by 21.6% in the fourth quarter. State of New Jersey Common Pension Fund D now owns 93,131 shares of the company’s stock valued at $2,556,000 after purchasing an additional 16,545 shares during the last quarter. Rhumbline Advisers boosted its holdings in BridgeBio Pharma by 2.3% in the fourth quarter. Rhumbline Advisers now owns 219,120 shares of the company’s stock valued at $6,013,000 after purchasing an additional 5,007 shares during the last quarter. Finally, Legato Capital Management LLC acquired a new stake in BridgeBio Pharma during the 4th quarter worth about $210,000. Institutional investors and hedge funds own 99.85% of the company’s stock.

Insider Buying and Selling at BridgeBio Pharma

In other BridgeBio Pharma news, major shareholder Global Investors Lp Viking sold 3,065,616 shares of the stock in a transaction dated Friday, January 31st. The shares were sold at an average price of $34.90, for a total value of $106,989,998.40. Following the completion of the sale, the insider now owns 22,055,375 shares in the company, valued at approximately $769,732,587.50. This represents a 12.20 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Neil Kumar sold 326,932 shares of the firm’s stock in a transaction that occurred on Tuesday, January 28th. The stock was sold at an average price of $36.29, for a total transaction of $11,864,362.28. Following the completion of the transaction, the chief executive officer now directly owns 5,371,515 shares in the company, valued at $194,932,279.35. This trade represents a 5.74 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 3,579,739 shares of company stock worth $125,411,901. Corporate insiders own 24.66% of the company’s stock.

Analyst Ratings Changes

Several equities analysts have recently issued reports on BBIO shares. Scotiabank boosted their price objective on BridgeBio Pharma from $49.00 to $52.00 and gave the company a “sector outperform” rating in a report on Friday, February 21st. Cantor Fitzgerald restated an “overweight” rating and issued a $95.00 price objective on shares of BridgeBio Pharma in a research report on Friday, February 21st. Evercore ISI raised their price objective on shares of BridgeBio Pharma from $45.00 to $50.00 and gave the stock an “outperform” rating in a research note on Monday, December 23rd. Bank of America boosted their target price on shares of BridgeBio Pharma from $42.00 to $45.00 and gave the company a “buy” rating in a research note on Monday, November 25th. Finally, Citigroup raised their price target on shares of BridgeBio Pharma from $45.00 to $49.00 and gave the company a “buy” rating in a research report on Friday, February 21st. One equities research analyst has rated the stock with a hold rating and twelve have issued a buy rating to the stock. According to MarketBeat, BridgeBio Pharma presently has a consensus rating of “Moderate Buy” and a consensus price target of $51.67.

BridgeBio Pharma Trading Up 1.9 %

Shares of BridgeBio Pharma stock opened at $34.90 on Friday. BridgeBio Pharma, Inc. has a twelve month low of $21.62 and a twelve month high of $39.47. The firm has a market capitalization of $6.64 billion, a PE ratio of -12.25 and a beta of 1.07. The firm’s 50-day moving average price is $32.68 and its 200 day moving average price is $28.29.

BridgeBio Pharma (NASDAQ:BBIO) last released its earnings results on Thursday, February 20th. The company reported ($1.31) earnings per share for the quarter, missing the consensus estimate of ($1.09) by ($0.22). The firm had revenue of $5.88 million during the quarter, compared to analyst estimates of $4.04 million. On average, sell-side analysts predict that BridgeBio Pharma, Inc. will post -3.67 EPS for the current fiscal year.

BridgeBio Pharma Profile

BridgeBio Pharma, Inc, a commercial-stage biopharmaceutical company, discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases and cancers. Its products in development programs include AG10, a next-generation oral small molecule near-complete TTR stabilizer that is in Phase 3 clinical trial for the treatment of TTR amyloidosis, or transthyretin amyloid cardiomyopathy (ATTR-CM); low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor, which is in Phase 3 double-blinded, placebo-controlled pivotal study for the treatment option for children with achondroplasia; and BBP-631, an AAV5 gene transfer product candidate that is in Phase 1/2 clinical trial for the treatment of congenital adrenal hyperplasia, or CAH, driven by 21-hydroxylase deficiency, or 21OHD.